Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Olema Pharmaceuticals (OLMA) has provided an announcement.
Olema Pharmaceuticals has shared promising interim results from a Phase 1b/2 trial combining palazestrant with ribociclib to treat ER+/HER2- metastatic breast cancer, which showed a high clinical benefit rate and good tolerance levels among patients. The study revealed that the combination therapy did not increase toxicity and maintained a favorable safety profile. These findings support further clinical development of the drug duo as a potential first-line treatment, which will be presented at the ESMO Breast Cancer Annual Congress.
For detailed information about OLMA stock, go to TipRanks’ Stock Analysis page.